SCHEMBL30765714

SCHEMBL30765714

CCCCOC(=O)Cn1c(S(C)(=O)=O)ncc(NCCCc2ccccc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 3/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 2/20 0.40
ASPH Q12797 2/20 0.40
RIOX2 Q8IUF8 2/20 0.40
KDM8 Q8N371 2/20 0.40
ALDH1A1 P00352 3/20 0.40
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765630 0.87 GAA (0.47) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30765606 0.85 MEN1 (0.44) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30765613 0.82 GAA (0.50) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30766150 0.80 GAA (0.52) MEN1KMT2AL3MBTL1GAALMNA
SCHEMBL30765817 0.80 GAA (0.42) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30765524 0.79 GAA (0.44) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30765958 0.79 GAA (0.42) L3MBTL1GAATSHRALDH1A1TP53
SCHEMBL30765744 0.77 BCHE (0.38) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL30765667 0.75 GAA (0.56) MEN1KMT2AL3MBTL1GAAPOLB
SCHEMBL30766080 0.75 MEN1 (0.45) MEN1KMT2AL3MBTL1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed